Research programme: anticancer therapeutics - Hercules Pharmaceuticals

Drug Profile

Research programme: anticancer therapeutics - Hercules Pharmaceuticals

Alternative Names: CB 7993113; HP 163

Latest Information Update: 20 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boston University
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Aryl hydrocarbon receptor antagonists; Cytochrome P-450 enzyme system modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Solid tumours

Most Recent Events

  • 17 Apr 2018 Preclinical trials in Solid tumours in Netherlands (unspecified route) (Hercules pharmaceuticals Pipeline, April 2018)
  • 16 Apr 2018 Pharmacodynamics data from a preclinical trial in Colon cancer model presented at the 109th Annual Meeting of the American Association for Cancer Research(AACR-2018)
  • 02 Nov 2015 Pharmacodynamics data from a preclinical study in cancer models released by Hercules Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top